To Improve Outcomes, We Must Find Ways to Optimize Prevention, Diagnosis and Treatment Across Cancers
August 15, 2019 – Len Lichtenfeld, M.D.
Currently Viewing
Lymphadenectomy in Ovarian Cancer: The Case for Staying in Place
August 19, 2019 – Beth Fand Incollingo
The Gift of Cancer Registries
August 16, 2019 – Marilyn Fenichel
To Improve Quality of Life and Health Outcomes, Seek Supportive Care
August 22, 2019 – Mike Hennessy, Sr.
A Look Inside a Supportive Care Clinic
August 22, 2019 – Beth Fand Incollingo
Reducing the Risk for Esophageal Cancer
August 21, 2019 – Leah Lawrence
Thinking Outside the Box With Esophageal Cancer Treatment
August 21, 2019 – Leah Lawrence
Dream Sequence
August 21, 2019 – Tracy Ahrens
Remaining Ever Vigilant in Cancer Screening
August 20, 2019 – Tara Kirk
Making Headway Against a Common and Disruptive Problem: Lymphedema
August 23, 2019 – Debu Tripathy, M.D.
Surprised by Side Effects
August 26, 2019 – Corinne Cleveland
Agents of Choice
August 26, 2019 – Jerry A. Barbee Jr., Pharm.D., Glenn Schulman, Pharm.D., Matthew Bailey, Meagan Balding and Amanda Boyer
Our Sisters' Keepers
August 23, 2019 – LaTonya Wilson
Taking on Pancreatic Cancer
August 27, 2019 – Tommy Thompson

Lymphadenectomy in Ovarian Cancer: The Case for Staying in Place

Removing lymph nodes that appear unaffected by ovarian cancer won’t help and might hurt.
BY Beth Fand Incollingo
PUBLISHED August 19, 2019
If advanced ovarian cancer has not visibly spread to a patient’s lymph nodes, removing the nodes is not only unnecessary but potentially harmful, researchers report.

Taking out normal-looking lymph nodes in the pelvis or abdomen during complete surgical removal of ovarian cancer did not increase survival, hasten disease progression or improve quality of life. However, removing the lymph nodes — known as lymphadenectomy — did increase postoperative complications, according to Dr. Philipp Harter of Kliniken Essen-Mitte in Germany and colleagues. Their study was published in the New England Journal of Medicine in February 2019.

Although more than half of the patients who underwent lymphadenectomy were later found to have disease that had spread to lymph nodes, excising the nodes did not translate into longer life or time without disease progression, the researchers found.

The authors embarked on the study to help end the debate over whether patients with ovarian cancer should have apparent- ly healthy lymph nodes in the pelvis or abdomen removed to prevent any microscopic disease there from spreading.

Between 2008 and 2012, the trial, Lymphadenectomy in Ovarian Neoplasms (LION), enrolled 647 patients with newly diagnosed stage 2b through 4 ovarian cancer who had no lymph nodes that were enlarged or appeared to the eye, during surgery, to be affected by cancer. Of those women, 323 were randomly assigned to undergo lymph node removal and 324 to forgo it. Those who underwent lymphadenectomy had a median of 57 nodes taken out — 35 pelvic and 22 abdominal.

Median overall survival was similar in both groups — 69.2 months in those who did not have lymph nodes removed and 65.5 months in those who did. The median time from the study’s start until disease progression was 25.5 months in both groups. Pathology findings showed that 55.7% of the women in the lymphadenectomy group had microscopic disease in lymph nodes at the time of surgery.

Serious postoperative complications occurred more frequently in the lymphadenectomy group: A second surgery was performed in 12.4% of those who underwent lymph node removal and 6.5% of those who did not, and the rate of death within 60 days of surgery was 3.1% in the lymphadenectomy group versus 0.9% in the non-lymphadenectomy group. The researchers also found that lymph- adenectomy increased the duration of surgery, amount of blood loss, need for postoperative intensive care, presence of lymph cysts and infection rate. Lymphedema, chronic swelling that results from fluid buildup caused by lymph node removal or other factors such as infection or cancer itself, occurred in 13 patients in the lymphadenectomy group and six in the non-lymphadenectomy group. The researchers found that quality-of-life differences between the two groups were not large enough to be clinically relevant.

“In this trial, patients with advanced ovarian cancer who underwent macroscopically complete resection did not benefit from systematic lymphadenectomy,” they wrote. “In contrast, lymphadenectomy resulted in treatment bur- den and harm to patients.”
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Ovarian Cancer CURE discussion group.

Related Articles


Sign In

Not a member? Sign up now!

Sign Up

Are you a member? Please Log In